<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646685</url>
  </required_header>
  <id_info>
    <org_study_id>07-0498-B</org_study_id>
    <nct_id>NCT00646685</nct_id>
  </id_info>
  <brief_title>Duct-to-duct vs Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation</brief_title>
  <official_title>Prospective Randomized Trial for Comparison of Duct-to-duct and Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to empirically determine whether one of 2 surgical techniques&#xD;
      commonly used for bile duct reconstruction during living donor liver transplantation results&#xD;
      in fewer biliary complications. Also, this study may identify patient group(s) that&#xD;
      particularly benefit from a particular technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the incidence of biliary complications (bile leaks&#xD;
      and strictures) following duct-to-duct and roux-en-y biliary reconstruction during right lobe&#xD;
      living donor liver transplantation.&#xD;
&#xD;
      Biliary complications are much more common with right lobe living donor liver grafts than&#xD;
      with whole organ grafts and are considered a major limitation of this surgery. Two surgical&#xD;
      techniques are currently used for biliary reconstruction and each has its&#xD;
      advantages/disadvantages. However, it is unclear which technique leads to fewer biliary&#xD;
      complications. Retrospective studies which examine biliary complication rates may be hampered&#xD;
      by such factors as a surgeon's bias or inexperience with a particular technique. Therefore a&#xD;
      prospective randomized trial is needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biliary complications defined as leaks and strictures within the first year post LDLT;</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft and patient survival</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital-stay and ICU-stay</measure>
    <time_frame>within first 30 days after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any infection or rejection episodes</measure>
    <time_frame>1 year post- transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to full oral nutrition</measure>
    <time_frame>within 30 days of discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical technique: duct-to-duct biliary reconstruction</intervention_name>
    <description>surgical reconstruction</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical technique: roux-en-y biliary reconstruction</intervention_name>
    <description>surgical reconstruction</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with end-stage liver disease&#xD;
&#xD;
          -  living donor liver transplantation using right hemi-liver as graft&#xD;
&#xD;
          -  duct anastomosis possible at time of surgery&#xD;
&#xD;
          -  donor and recipient aged 18 yrs or older&#xD;
&#xD;
          -  written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  duct anastomosis not possible&#xD;
&#xD;
          -  acute fulminant liver failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Selzner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

